Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions.
Company facts
| Company | Aardvark Therapeutics, Inc. |
|---|---|
| Symbol | AARD |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $109.64M (Massive market data, 2026-09-10) |
| Employees | 28 |
| Country | United States |
| Website | https://aardvarktherapeutics.com |
Trading — Aardvark Therapeutics, Inc.
| Last price | $5.13 |
|---|---|
| Change | 2.40% |
| Previous close | $5.01 |
| Day range | $4.97 – $5.54 |
| 50-day average | $6.30 |
| 200-day average | $7.87 |
| Average volume | 230,836 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $-3.19 |
|---|---|
| Price / book | 1.47 |
| Enterprise value / EBITDA | -0.48 |
| Debt / equity | 0.00 |
| Current ratio | 12.63 |
| Dividend yield | 0.00% |
| Free cash flow | -$69.41M |
| Cash ratio | 11.56 |
| Enterprise value | $35.79M |
Reported 2026-09-10
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for AARD are on the IntelTrends dashboard.